Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
Key Highlights
- ➤AFRRI will evaluate Entolimod’s post-radiation therapeutic efficacy in a GI-ARS model
- ➤NIAID/RNCP fully funds the therapeutic study under an agreement with USU/AFRRI
- ➤Top-line results are anticipated in early December
- ➤Mice receive Entolimod or saline 24 hours after radiation exposure; survival is primary endpoint
- ➤Positive safety results preceded advancement into therapeutic efficacy testing
Expert Statements
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“NIAID's decision to move into therapeutic efficacy testing at AFRRI gives Entolimod a clear next milestone following the positive safety findings,”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“The central question is now whether treatment after radiation exposure can improve survival in a model designed to isolate gastrointestinal injury.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“This fully funded study provides an opportunity to evaluate that potential while preserving Valion's capital and generating critical efficacy data to guide Entolimod towards its next stage of development.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“GI-ARS remains a critical challenge in the development of medical countermeasures,”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“Demonstrating a survival benefit in this model would underscore a novel and clinically significant milestone for Entolimod and further strengthen its potential role as a medical countermeasure for radiation emergencies.”
Dean Zikria, Interim Chief Executive Officer of Valion Bio
“We would like to thank AFRRI and NIAID for their continued support and look forward to the results from this key study.”
SAN ANTONIO, TX / ACCESS Newswire / October 30, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced that the Armed Forces Radiobiology Research Institute ("AFRRI") will be evaluating the therapeutic efficacy of Entolimod. This phase will evaluate whether treatment administered after radiation exposure improves survival in a model designed to assess gastrointestinal acute radiation syndrome ("GI-ARS").
The therapeutic study is fully funded by the National Institute of Allergy and Infectious Diseases ("NIAID")/Radiation and Nuclear Countermeasures Program ("RNCP") under an Interagency Agreement with the Uniformed Services University ("USU")/AFRRI. Top-line results are anticipated in early December.
Get started
Create a free account to read the full story.